A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine

BJU International

Volumn 109, Issue 6, 2012, Pages 941-948

  Zuiverloon, Tahlita C M ^a,b   Beukers, Willemien ^a   Van Der Keur, Kirstin A ^a   Munoz, Jesrael R ^a   Bangma, Chris H ^b   Lingsma, Hester F ^a   Eijkemans, Marinus J C ^a   Schouten, Jan P ^c   Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Urology ^*  (Netherlands)

^c MRC HOLLAND   (Netherlands)

Author keywords

bladder cancer; methylation; surveillance; urine

Indexed keywords

ADULT; AGED; APC GENE; AREA UNDER THE CURVE; ARTICLE; BCL2 GENE; BLADDER CANCER; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CDH13 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DNA ISOLATION; ESR1 GENE; GENE; HISTOPATHOLOGY; HTERT GENE; HUMAN; MALE; METHYLATION; MGMT GENE; MSH6 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NON MUSCLE INVASIVE BLADDER CANCER; PAX5 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PTEN GENE; RARB GENE; RASSF1A GENE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TIMP3 GENE; TP53 GENE; URINALYSIS; URINE; WIF1 GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; HUMANS; METHYLATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ENDOTHELIN B; SENSITIVITY AND SPECIFICITY; TELOMERASE; URINARY BLADDER NEOPLASMS; URINE;

EID: 84857646000     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10428.x     Document Type: Article

References (38)

1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R,. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30 (Pubitemid 38041357)
2. Hedelin H, Holmang S, Wiman L,. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002; 36: 344-7 (Pubitemid 35373621)
3. Mariappan P, Smith G,. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005; 173: 1108-11 (Pubitemid 40380512)
4. Kiemeney LA, Witjes JA, Verbeek AL, Heijbroek RP, Debruyne FM,. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 1993; 67: 806-12 (Pubitemid 23101564)
5. Grossman HB, Gomella L, Fradet Y, et al,. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 62-7 (Pubitemid 46908731)
6. Jocham D, Witjes F, Wagner S, et al,. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862-6 (Pubitemid 41140613)
7. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M,. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135-8 (Pubitemid 37549108)
8. Witjes JA, Douglass J,. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 2007; 4: 542-9 (Pubitemid 47554987)
9. Grossman HB, Soloway M, Messing E, et al,. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Jama 2006; 295: 299-305 (Pubitemid 43112958)
10. Babjuk M, Oosterlinck W, Sylvester R, et al,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
11. Casetta G, Gontero P, Zitella A, et al,. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder. Urol Int 2000; 65: 100-5
12. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL,. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997; 50: 882-7
13. Ramakumar S, Bhuiyan J, Besse JA, et al,. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161: 388-94
14. van Rhijn BW, van der Poel HG, van der Kwast TH,. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47: 736-48 (Pubitemid 40745338)
15. Suzuki H, Gabrielson E, Chen W, et al,. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-9
16. Khin SS, Kitazawa R, Win N, et al,. BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int J Cancer 2009; 125: 328-38
17. Aleman A, Adrien L, Lopez-Serra L, et al,. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008; 98: 466-73 (Pubitemid 351161244)
18. Catto JW, Azzouzi AR, Rehman I, et al,. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23: 2903-10 (Pubitemid 46224108)
19. Yates DR, Rehman I, Abbod MF, et al,. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13: 2046-53 (Pubitemid 46649871)
20. Tada Y, Wada M, Taguchi K, et al,. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002; 62: 4048-53 (Pubitemid 34791073)
21. Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E,. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 2001; 159: 831-5 (Pubitemid 32847174)
22. Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT,. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007; 28: 1745-51 (Pubitemid 47289037)
23. Chan MW, Chan LW, Tang NL, et al,. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003; 104: 611-6 (Pubitemid 36337261)
24. Chan MW, Chan LW, Tang NL, et al,. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8: 464-70 (Pubitemid 34193966)
25. Friedrich MG, Weisenberger DJ, Cheng JC, et al,. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004; 10: 7457-65 (Pubitemid 39557507)
26. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW,. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006; 25: 1984-8
27. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P,. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004; 10: 1887-93 (Pubitemid 38375544)
28. Hoque MO, Begum S, Topaloglu O, et al,. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006; 98: 996-1004 (Pubitemid 44288164)
29. Renard I, Joniau S, van Cleynenbreugel B, et al,. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010; 58: 96-104
30. Kim YK, Kim WJ,. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 2009; 16: 17-22
31. Nygren AO, Ameziane N, Duarte HM, et al,. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005; 33: e128
32. Urakami S, Shiina H, Enokida H, et al,. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006; 12: 2109-16
33. Yu J, Zhu T, Wang Z, et al,. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007; 13: 7296-304
34. Stoehr R, Zietz S, Burger M, et al,. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005; 47: 58-63 (Pubitemid 39575719)
35. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA,. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170: 433-7 (Pubitemid 36870218)
36. Herr HW, Donat SM,. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102: 1242-6
37. Kolozsy Z,. Histopathological 'self control' in transurethral resection of bladder tumours. Br J Urol 1991; 67: 162-4
38. van der Aa MN, Steyerberg EW, Bangma C, van Rhijn BW, Zwarthoff EC, van der Kwast TH,. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol 2010; 183: 76-80